Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial

Abstract

BES=biodegradable polymer biolimus-eluting stent, SES=durable polymer sirolimus-eluting stent, PCI=percutaneous coronary intervention. Note that we have no reliable data on the number of patients assessed for eligibility Baseline characteristics Biodegradable polymer BES (N=857) Durable polymer SES (N=850) Age (years) 64•6 (10•8) 64•5 (10•7) Male 643 (75•0%) 634 (74•6%) Diabetes mellitus 223 (26•0%) 191 (22•5%) Insulin requiring 81 (9•5%) 77 (9•1%) Hypertension 630 (73•5%) 618 (72•7%) Hypercholesterolemia 560 (65•3%) 580 (68•2%) Current smoker 206 (24•0%) 214 (25•2%) Family history of coronary artery disease 339 (39•6%) 374 (44•0%)

Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts

“…Similarly, in the Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent (DELAYED RRISC) study 15 , rates of MACE amounted to 58% among SES-treated patients at a median follow-up of 32 months. These figures contrast with rates of MACE in the range of 20% among unselected patients enrolled in all-comers studies with the predominant treatment of native coronary artery lesions [16][17][18] .…”

2013 Esc Guidelines on the Management of Stable Coronary Artery Disease

“…имплантации стентов первого поколения [172]. СЛП нового поколения ассоциировались с мень-шими уровнями развития тромбоза внутри стента [391,392], и недавно полученные данные из реги-стров и рандомизированных, контролируемых исследований свидетельствуют о том, что более короткий период ДАТ может быть достаточным у стабильных коронарных пациентов [393][394][395][396]. Учитывая отношение риска и пользы для ДАТ сро-ком до 6 месяцев (и в то же время ожидая больше информации из проводящихся сейчас исследова-ний с разными периодами лечения, в том числе более 1 года), мы одобрили современную рекомен-дацию ЕОК по ДАТ сроком от 6 до 12 месяцев у пациентов с СИБС, проходящих реваскуляриза-цию путем ЧКВ с имплантацией СЛП новейшего поколения (см.…”

Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials

“…This design has been hypothesised to reduce the incidence of late adverse events, which have been linked to durable polymer coatings in some patients 1,2 . Studies of BP-DES have demonstrated safety and long-term efficacy versus durable polymer DES in a broadly inclusive patient population, with a reduction in very late definite stent thrombosis seen up to four years 2 .…”